Rinsho Shinkeigaku (Clinical Neurology)

Symposium 09

Fisher syndrome and Bickerstaff brainstem encephalitis

Satoshi Kuwabara, M.D.1)

1)Department of Neurology, Graduate School of Medicine, Chiba University

This review described current status and perspectives of treatment for immune-mediated neuropathies, such as Guillain-Barre syndrome, chronic inflammatory demyelinating polyneuropathy (CIDP), multifocal motor neuropathy, and demyelinating neuropathy with anti-MAG neuropathy. corticosteroids, immunoglobulin therapy, and plasmapheresis are conventional treatments for these neuropathies, but the responsiveness to the treatments significantly differ among the disorders. Promising new treatment options include anti-complement monoclonal antibody (Eculizumab, anti-C5) for Guillain-Barre syndrome, and rituximab (anti-CD20) for anti-MAG neuropathy. For CIDP, different treatments would be required according to the clinical subtypes; typical CIDP and asymmetric variabt). For multifocal neuropathy, maintainance treatment with immunoglobulin is necessary.
Full Text of this Article in Japanese PDF (234K)

(CLINICA NEUROL, 54: 1056|1057, 2014)
key words: Guillain-Barre syndrome, chronic inflammatory demyelinating polyneuropathy, multifocal mptpr neuropathy, complement inhibitor

(Received: 22-May-14)